<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482846</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000547155</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2006-119</secondary_id>
    <nct_id>NCT00482846</nct_id>
    <nct_alias>NCT01654744</nct_alias>
  </id_info>
  <brief_title>Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma</brief_title>
  <official_title>Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the
      growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Keratinocyte growth factors, such as palifermin, may help prevent symptoms of mucositis, or
      mouth sores, in patients receiving melphalan before a peripheral stem cell transplant for
      multiple myeloma.

      PURPOSE: This phase I trial is studying the side effects and best dose of melphalan when
      given together with palifermin in treating patients undergoing an autologous peripheral stem
      cell transplant for stage II or stage III multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose of high-dose melphalan when administered with
           palifermin in patients undergoing autologous peripheral blood stem cell transplantation
           for stage II or III multiple myeloma.

      Secondary

        -  Assess overall response (complete and partial response and stable disease) in these
           patients at 28 and 100 days post-transplantation.

        -  Assess the efficacy of palifermin as a cytoprotective agent in reducing incidence and
           duration of mucositis in patients treated with this regimen.

        -  Assess patient-reported outcomes and impact of palifermin on quality of life of these
           patients.

        -  Assess the qualitative and quantitative toxicities of this regimen in these patients.

      OUTLINE: This is a dose-escalation study of melphalan. Patients are stratified according to
      creatinine clearance (normal vs &lt; 60 mL/min).

      Patients receive high-dose melphalan IV on day -2 and palifermin IV on days -5 to -3 and 1-3.
      Patients undergo autologous peripheral blood stem cell transplantation on day 0.

      In each stratum, cohorts of 3-6 patients receive escalating doses of melphalan until the
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

      Patients complete questionnaires about overall health, mouth and throat soreness (MTS), and
      activity limitations due to MTS once daily on days -5 to 28.

      After completion of study treatment, patients are followed at days 28 and 100 and then
      periodically thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of melphalan when treated with palifermin to prevent mucositis</measure>
    <time_frame>Days -5, -4, -3, 2, +1, +2 and +3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>Days -5, -4, -3, 2, +1, +2 and +3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of Palifermin as a cytoprotective agent in reducing incidence and duration of Grade 3 and 4 mucositis due to high dose Melphlan</measure>
    <time_frame>Day -5 to Day +28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>At Day 28 and Day100 after autologous transplant when treated with combination of palifermin and Melphalan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in incidence and duration of mucositis</measure>
    <time_frame>Days -5 to Day +28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Mucositis</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Palifermin &amp; Melphalen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is &gt;40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:
Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;
Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. &lt;60)adm. via I.V.:
Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is &gt;40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3</description>
    <arm_group_label>Palifermin &amp; Melphalen</arm_group_label>
    <other_name>Kepivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:
Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;
Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. &lt;60)adm. via I.V.:
Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;</description>
    <arm_group_label>Palifermin &amp; Melphalen</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Day -5 to Day +28</description>
    <arm_group_label>Palifermin &amp; Melphalen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous peripheral blood stem cell transplantation</intervention_name>
    <description>Day 0</description>
    <arm_group_label>Palifermin &amp; Melphalen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Day -5 to Day +28</description>
    <arm_group_label>Palifermin &amp; Melphalen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma

               -  Stage II or III disease

          -  Must have undergone successful stem cell mobilization (≥ 2.0 x 10^6 CD34+ cells/kg)

          -  No oral lesions from any other etiology

          -  No unhealed mucositis from induction treatment

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  Amylase and lipase normal

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 3 times ULN

          -  Creatinine normal (stratum 1 only)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No HIV positivity

          -  No history of allergic reaction attributed to melphalan

          -  No uncontrolled illness, including, but not limited to, any of the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No hepatitis B or C positivity

          -  No prior or concurrent pancreatitis

          -  No known sensitivity to any of the study drugs, including E. coli-derived products

        PRIOR CONCURRENT THERAPY:

          -  Prior bone marrow or stem cell transplantation allowed

          -  No prior palifermin

          -  More than 30 days since prior investigational agents

          -  No concurrent dialysis

          -  No concurrent amifostine

          -  No concurrent prophylactic oral cryotherapy during melphalan administration

          -  No concurrent mouthwash solutions containing any of the following:

               -  Chlorhexidine

               -  Hydrogen peroxide

               -  Diphenhydramine hydrochloride

          -  No concurrent recombinant interleukin-11 or sargramostim (GM-CSF)

          -  No concurrent sucralfate in suspension form

               -  Sucralfate tablets allowed

          -  No concurrent povidone-iodine rinses

          -  No concurrent glutamine as a prophylactic agent for mucositis

          -  No other concurrent investigational agents

          -  No concurrent antithymocyte globulin suppression or alemtuzumab

          -  No concurrent rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muneer H. Abidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Muneer Abidi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mucositis</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

